re.Mind Capital is a specialist venture fund focused exclusively on mental health, neurological health, BCI, digital health, and new pharma. It operates within the Apeiron ecosystem and has built one of the most concentrated neuro-focused portfolios among dedicated funds. Compared with broader healthcare investors, its thesis is unusually narrow and explicit.

Its portfolio includes Blackrock Neurotech, Motif Neurotech, and Precision Neuroscience, covering major modalities within implantable and minimally invasive brain-computer interfaces. This concentration makes re.Mind one of the clearest dedicated BCI investors in the market. It is especially notable for treating neurotechnology, mental health, and next-generation treatment platforms as one connected investment universe.

The fund invests mainly in the United States, with secondary activity in Europe. For neurotech founders, re.Mind is a high-priority specialist target, particularly in BCI, neuropsychiatry, and broader brain-health platforms. It is one of the most thesis-driven and sector-specific investors in the neurotechnology landscape.